PubRank

Vincenzo Bronte

Author PubWeight™ 132.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012 12.19
2 Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006 6.61
3 Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007 6.31
4 Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2005 6.05
5 Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012 5.44
6 Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010 4.62
7 The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007 4.37
8 Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008 4.36
9 Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006 4.20
10 High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004 3.94
11 Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010 3.88
12 Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002 3.56
13 Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010 3.18
14 Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2003 2.65
15 IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009 2.64
16 PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014 2.51
17 Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A 2005 2.49
18 Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011 2.06
19 A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011 2.03
20 Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 2012 1.87
21 Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014 1.69
22 Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009 1.68
23 Control of immune response by amino acid metabolism. Immunol Rev 2010 1.63
24 Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. Cell Host Microbe 2013 1.62
25 Part I: Vaccines for solid tumours. Lancet Oncol 2004 1.61
26 Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep 2012 1.59
27 Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2005 1.56
28 Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev 2007 1.55
29 Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood 2011 1.47
30 Role of arginine metabolism in immunity and immunopathology. Immunobiology 2007 1.33
31 Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 2008 1.31
32 Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res 2005 1.28
33 Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol 2011 1.25
34 Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood 2009 1.20
35 Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol 2014 1.08
36 Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest 2015 1.07
37 miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity 2013 1.07
38 Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol 2011 1.07
39 Modulation of human T-cell functions by reactive nitrogen species. Eur J Immunol 2011 1.03
40 IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 2010 1.02
41 Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol 2011 1.02
42 Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Rev 2011 1.01
43 Retracted High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res 2012 1.01
44 In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res 2009 1.00
45 Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res 2008 0.99
46 The pros and cons of chemokines in tumor immunology. Trends Immunol 2012 0.99
47 Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin Cancer Biol 2007 0.97
48 Cancer vaccines: pessimism in check. Nat Med 2004 0.97
49 Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom 2014 0.95
50 Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid 2007 0.95
51 Measurement of myeloid cell immune suppressive activity. Curr Protoc Immunol 2010 0.94
52 Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes. Cancer Res 2004 0.90
53 Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol 2010 0.89
54 Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. Blood 2013 0.89
55 Role of microRNAs in HTLV-1 infection and transformation. Mol Aspects Med 2010 0.85
56 Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis 2009 0.84
57 Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells. Neoplasia 2012 0.83
58 Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. BMC Cell Biol 2012 0.83
59 Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. J Virol 2014 0.83
60 L-glutamine is a key parameter in the immunosuppression phenomenon. Biochem Biophys Res Commun 2012 0.82
61 Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. Eur J Immunol 2009 0.82
62 Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. Biomatter 2014 0.81
63 Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom 2014 0.80
64 The transcriptional response in human umbilical vein endothelial cells exposed to insulin: a dynamic gene expression approach. PLoS One 2010 0.78
65 Myeloid-derived suppressor cells exhibit two bioenergetic steady-states in vitro. J Biotechnol 2011 0.78
66 Smoothing T cell roads to the tumor: Chemokine post-translational regulation. Oncoimmunology 2012 0.77
67 CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response. Cancer Immunol Immunother 2004 0.77
68 T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell 2016 0.76
69 Nitric oxide affects immune cells bioenergetics: long-term effects of nitric-oxide derivatives on leukaemic Jurkat cell metabolism. Immunobiology 2012 0.75
70 Methotrexate for immunosuppression in life-supporting pig-to-cynomolgus monkey renal xenotransplantation. Xenotransplantation 2003 0.75
71 Tumor-Induced Myeloid-Derived Suppressor Cells. Microbiol Spectr 2016 0.75